

N24S asparaginase: a new option for Acute Lymphoblastic Leukaemia treatment

Claudia SCOTTI - *University of Pavia*

L-asparaginases are used as first-line drugs for the treatment of Acute Lymphatic Leukaemia (ALL). Those currently used in the clinic are characterised by high in vivo instability, a short half-life, and the need for multiple administrations. Moreover, they are sensitive to specific enzymes that are overexpressed by tumour cells and contribute to rapid drug elimination. We have patented a new variant of asparaginase that has better characteristics than the pre-existing ones, making it an interesting alternative to reduce the number of administrations and address other issues related to ALS treatment.